For patients · Medication guide
Ustekinumab
anti-IL-12/23, Stelara
Are you a clinician? See the clinical version of this page.
The short versionUstekinumab is a biologic medicine that blocks two inflammation signals, IL-12 and IL-23. It is used in psoriatic arthritis and psoriasis, and can help both the joints and the skin.
How you take it
Given as an injection under the skin: a dose at the start and 4 weeks later, then every 12 weeks. It blocks IL-12 and IL-23 and is used mainly for psoriatic arthritis. You will be checked for tuberculosis first.
- Psoriatic arthritis: An injection at week 0 and week 4, then every 12 weeks.
Tests while you take it
You are checked for tuberculosis before starting. Report signs of infection.
What to know
Common side effects
The most common effects are reactions where the injection is given and a higher chance of infections. It is generally well tolerated.
Tests and monitoring
Before starting, your team checks for hidden infections such as tuberculosis. While on treatment, tell your team about infections.
Important cautions
As with other medicines that calm the immune system, infections need watching, and live vaccines are timed with your team.
+Planning a pregnancy? This medicine has separate, reviewed reproductive-health guidance. See the pregnancy guide for this medicine.
iThis page helps you prepare a conversation with your care team. It does not replace individual medical advice. Always confirm your own plan with your rheumatology team.
!
What to watch for
- Signs of infection with a fever, or an infection that does not clear.
- Feeling generally unwell in a way that does not settle.